Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders: A randomized clinical cross-over trial

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{4b2d6bde9f2c4e12957c3d393acac203,
title = "No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders: A randomized clinical cross-over trial",
abstract = "The objective was to investigate whether resveratrol (RSV) can improve exercise capacity in patients with fatty acid oxidation (FAO) disorders. The study was a randomized, double-blind, cross-over trial. Nine patients with very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency or carnitine palmitoyl transferase (CPT) II deficiency were randomized to receive either 8 weeks of 1000 mg day-1 RSV or placebo (P) followed by a 4-weeks wash-out period and subsequently 8 weeks of the opposite treatment. Primary outcome measures were heart rate and FAO as measured via stable isotope technique during constant workload exercise. Secondary outcome measures included fat and glucose metabolism; perceived exertion; as well as subjective measures of energy expenditure, fatigue, and daily function. Eight participants completed the trial. Heart rate did not differ at the end of exercise after treatment with RSV vs placebo (P = .063). Rate of oxidation of palmitate at end of exercise was not different with 1.5 ± 0.8 (RSV) vs 1.3 ± 0.6 (P) μmol kg-1 min-1 (P = .109). Secondary outcomes did not change except for increased plasma glycerol and decreased plasma glucose levels at the end of exercise after treatment with RSV vs placebo. A daily dose of 1000 mg resveratrol does not improve exercise capacity or FAO during exercise in patients with CPTII or VLCAD deficiencies.",
keywords = "Acyl-CoA Dehydrogenase, Long-Chain, Carnitine O-Palmitoyltransferase/deficiency, Congenital Bone Marrow Failure Syndromes, Cross-Over Studies, Exercise Tolerance/physiology, Fatty Acids/metabolism, Humans, Lipid Metabolism, Inborn Errors/metabolism, Metabolism, Inborn Errors, Mitochondrial Diseases, Muscular Diseases, Oxidation-Reduction, Resveratrol/pharmacology",
author = "Storgaard, {Jesper H} and Nicoline L{\o}kken and Madsen, {Karen L} and Voermans, {Nicol C} and Pascal Lafor{\^e}t and Aleksandra Nadaj-Pakleza and C{\'e}line Tard and {van Hall}, Gerrit and John Vissing and {\O}rngreen, {Mette C}",
note = "{\textcopyright} 2022 SSIEM.",
year = "2022",
month = may,
doi = "10.1002/jimd.12479",
language = "English",
volume = "45",
pages = "517--528",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",
number = "3",

}

RIS

TY - JOUR

T1 - No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders

T2 - A randomized clinical cross-over trial

AU - Storgaard, Jesper H

AU - Løkken, Nicoline

AU - Madsen, Karen L

AU - Voermans, Nicol C

AU - Laforêt, Pascal

AU - Nadaj-Pakleza, Aleksandra

AU - Tard, Céline

AU - van Hall, Gerrit

AU - Vissing, John

AU - Ørngreen, Mette C

N1 - © 2022 SSIEM.

PY - 2022/5

Y1 - 2022/5

N2 - The objective was to investigate whether resveratrol (RSV) can improve exercise capacity in patients with fatty acid oxidation (FAO) disorders. The study was a randomized, double-blind, cross-over trial. Nine patients with very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency or carnitine palmitoyl transferase (CPT) II deficiency were randomized to receive either 8 weeks of 1000 mg day-1 RSV or placebo (P) followed by a 4-weeks wash-out period and subsequently 8 weeks of the opposite treatment. Primary outcome measures were heart rate and FAO as measured via stable isotope technique during constant workload exercise. Secondary outcome measures included fat and glucose metabolism; perceived exertion; as well as subjective measures of energy expenditure, fatigue, and daily function. Eight participants completed the trial. Heart rate did not differ at the end of exercise after treatment with RSV vs placebo (P = .063). Rate of oxidation of palmitate at end of exercise was not different with 1.5 ± 0.8 (RSV) vs 1.3 ± 0.6 (P) μmol kg-1 min-1 (P = .109). Secondary outcomes did not change except for increased plasma glycerol and decreased plasma glucose levels at the end of exercise after treatment with RSV vs placebo. A daily dose of 1000 mg resveratrol does not improve exercise capacity or FAO during exercise in patients with CPTII or VLCAD deficiencies.

AB - The objective was to investigate whether resveratrol (RSV) can improve exercise capacity in patients with fatty acid oxidation (FAO) disorders. The study was a randomized, double-blind, cross-over trial. Nine patients with very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency or carnitine palmitoyl transferase (CPT) II deficiency were randomized to receive either 8 weeks of 1000 mg day-1 RSV or placebo (P) followed by a 4-weeks wash-out period and subsequently 8 weeks of the opposite treatment. Primary outcome measures were heart rate and FAO as measured via stable isotope technique during constant workload exercise. Secondary outcome measures included fat and glucose metabolism; perceived exertion; as well as subjective measures of energy expenditure, fatigue, and daily function. Eight participants completed the trial. Heart rate did not differ at the end of exercise after treatment with RSV vs placebo (P = .063). Rate of oxidation of palmitate at end of exercise was not different with 1.5 ± 0.8 (RSV) vs 1.3 ± 0.6 (P) μmol kg-1 min-1 (P = .109). Secondary outcomes did not change except for increased plasma glycerol and decreased plasma glucose levels at the end of exercise after treatment with RSV vs placebo. A daily dose of 1000 mg resveratrol does not improve exercise capacity or FAO during exercise in patients with CPTII or VLCAD deficiencies.

KW - Acyl-CoA Dehydrogenase, Long-Chain

KW - Carnitine O-Palmitoyltransferase/deficiency

KW - Congenital Bone Marrow Failure Syndromes

KW - Cross-Over Studies

KW - Exercise Tolerance/physiology

KW - Fatty Acids/metabolism

KW - Humans

KW - Lipid Metabolism, Inborn Errors/metabolism

KW - Metabolism, Inborn Errors

KW - Mitochondrial Diseases

KW - Muscular Diseases

KW - Oxidation-Reduction

KW - Resveratrol/pharmacology

UR - http://www.scopus.com/inward/record.url?scp=85124483103&partnerID=8YFLogxK

U2 - 10.1002/jimd.12479

DO - 10.1002/jimd.12479

M3 - Journal article

C2 - 35066899

VL - 45

SP - 517

EP - 528

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 3

ER -

ID: 78315949